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Summary
Objective: To evaluate the effect of therapeutic education and functional readaptation (TEFR) on health-related quality of life (HRQL) in pa-
tients diagnosed with osteoarthritis on a waiting list for total knee replacement (TKR).
Methods: Randomized controlled trial of 9 months duration was conducted. One hundred consecutive outpatients (71 females, mean age 71
years (range 50e86), mean disease duration 11.84 10.52 months) were included. Patients were randomized in two groups. The intervention
group received TEFR added to conventional (pharmacological) treatment (n¼ 51). The control group received conventional (pharmacological)
treatment only (n¼ 49). The main outcome variable was self-reported HRQL measured by the Spanish version of Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcomes were general HRQL measured by Short Form Health Survey gen-
eral questionnaire (SF-36), number of visits to general physicians and their cost. Assessments were done at baseline and at 9 months.
Main results: Eighty patients completed the study. Signiﬁcant improvement in the WOMAC function was found at 9 months in the TERF group
with respect to the control group (P¼ 0.035). Consumption of analgesics increased signiﬁcantly in the TERF group compared with controls
(P¼ 0.036). Signiﬁcant improvements in pain (P¼ 0.027) measured by WOMAC and in bodily pain (P¼ 0.043) and physical function
(P¼ 0.031), measured by SF-36, were observed in the intervention group with respect to baseline.
Conclusions: The function dimension measured by WOMAC of patients who received both pharmacological treatment and TERF improved
with respect to the control group receiving only pharmacological treatment. This suggests that a program of TEFR during the period on the
waiting list for TKR may reduce the negative impact of this situation.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Musculoskeletal diseases have a great social impact in
terms of morbidity and the general health status, affecting
one in 10 Spaniards, 80% of whom suffer degenerative
rheumatism or osteoarthritis (OA)1. As in comparable coun-
tries, musculoskeletal diseases are the ﬁrst cause of disabil-
ity, especially in the elderly1,2. Disability and pain, the main
characteristics of knee OA, can result in substantial loss of
autonomy and quality of life, with surgical replacement of
the affected joint being indicated in many cases. However,
in the Spanish health service, demand for such interven-
tions vastly exceeds supply, resulting in long waiting lists1,3.
In a previous study, we showed that a group of patients
on the waiting list for total knee replacement (TKR)
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Received 2 June 2005; revision accepted 8 October 2005.279presented a substantial deterioration of health-related qual-
ity of life (HRQL)4. Possible reasons for this are delays in
a situation of high expectations, the absence of therapeutic
alternatives to conventional drug treatments (basically non-
steroidal anti-inﬂammatory drugs (NSAIDs)) and patient re-
sistance to these treatments. All these reasons may
contribute to a worsening of the quality of life of patients al-
ready affected by the negative effects of the disease4e8.
Various reports, mainly concerned with rheumatoid arthri-
tis (RA), have shown that educational programs in patients
with musculoskeletal diseases improve health outcomes
such as disability and pain9e11. As these diseases are usu-
ally chronic, patient participation in the control of the dis-
ease is essential.
Therapeutic patient education is deﬁned as any set of
planned educational activities organized to provide the pa-
tients knowledge and competence necessary to manage
their disease12.
The objective of the present study was to evaluate the ef-
fect of a program of therapeutic education and functional re-
adaptation (TEFR) on HRQL in patients diagnosed with OA
on a waiting list for TKR.
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SETTING AND PARTICIPANTS
The setting was an urban tertiary care center, the Hospi-
tal Clı´nic, Barcelona (Spain). Participants were 104 consec-
utive outpatients of all ages referred by the Orthopedic
Surgery Department to our TERF Unit, with knee OA ac-
cording to the Kellgren and Lawrence criteria13, who had
been on a waiting list for TKR for less than 6 months and
who consented to participate in the study. The study was
approved by the hospital Ethics Committee. Exclusion crite-
ria were functional illiteracy, inﬂammatory musculoskeletal
disease, metabolic or neoplasic disease and severe psy-
chopathology or comorbidity, deﬁned as a diagnosis in the
medical record severe enough that the patient could not
complete the TEFR program. Four patients were excluded
and the total number who participated in the study was 100.
TRIAL DESIGN
A randomized, controlled trial of 9 months duration was
conducted. A minimum of 48 patients in the intervention
group and 48 in the control group was calculated to detect
a difference of 0.3 in the function dimension of the West-
ern Ontario and McMaster Universities Osteoarthritis Index
(WOMAC)14 between the two groups, accepting a rate of
loss of 0.2, an alpha risk of 0.05 and a beta risk of 0.20 in
a bilateral contrast. Thus, the rate of losses during the fol-
low-up was estimated at 20%.
After giving consent, patients were randomized to the in-
tervention group, which received TERF added to conven-
tional (pharmacological) treatment (n¼ 51) or the control
group, which received conventional (pharmacological) treat-
ment only (n¼ 49). A randomization table generated by an
ad hoc program based on the pseudorandomized routine of
the STATA 5.0 (Stata Corp, TX, USA) statistical package
was used.
INTERVENTIONS
The intervention group followed a program of TERF for
patients with musculoskeletal diseases involving the lower
limbs, designed to improve pain and functional disability
and to increase patient disease self-management15,16.
The program was based on theories of social learning
and self-management17,18 and carried out using active
learning strategies19,20.
The 3-month program consisted of two individual visits
lasting about 30 min at ﬁrst week and at 3 months, and
two group sessions of about 90 min in weeks 3 and 4, for
a maximum of 10e12 patients, accompanied, when possi-
ble, by a relative or signiﬁcant other. All sessions took place
in the morning and were conducted by the same trained
health educator. All participants were provided with written
information on the contents of the sessions21.
These contents were centered on the consequences of
the disease on daily life and included principles of
economy/energy conservation and joint protection; evalua-
tion and control of pain (rest and positioning, ice and heat,
necessary length of application) and treatments recom-
mended for the management of knee OA22; demonstration
and use of assistive devices and tables of physical exer-
cises with no burden on the lower limbs, with speciﬁc
knee exercises to maintain and improve the strength of
muscles acting around the knee, the range of motion at
the knee joint, and locomotor function; and generalexercises to mobilize the joints and strengthen the muscu-
lature of the rest of the body. Patients were instructed to
increase the number of repetitions up to a maximum of
30 times, twice a day, for the knee exercises, and 10
times, once a day, for the general exercises, according
to individual tolerance to pain. The exercises were taught
in the group sessions. Patients were instructed to practice
the exercises at home in the week previous to the second
group session, in which all patients carried out the com-
plete table of exercises, supervised by the educator. Fol-
low-ups were performed in the individual visits. The
patients in the control group were also seen, individually,
twice by their physicians. Figure 1 shows a ﬂow-chart of
the program.
Bothgroupsof patients received3e4 g/day of paracetamol
alone or 2 g/day of paracetamol combined with 2400 mg/
day of ibuprofen or other NSAIDs. The dosage of NSAIDs
used was varied according to individual patient needs.
OUTCOME MEASURES
The primary outcome measure was self-reported HRQL
at 9 months, evaluated by the knee-speciﬁc questionnaire
of the WOMAC LK 3.0 adapted to the Spanish population.
WOMAC has three dimensions: pain, stiffness, and func-
tion. These dimensions produce scores of 0e20, 0e8,
0e68, respectively, with higher scores indicating more
pain, stiffness, and reduced physical function14,23.
Secondary outcome measures included HRQL measured
by the Spanish version of the Short Form Health Survey
general questionnaire (SF-36). This questionnaire has eight
separate dimensions with scores ranging from 0 (worst) to
100 (best): physical function, social function, role limitations
due to physical problems, role limitation due to emotional
problems, general mental health, energy, bodily pain, and
general health perceptions24,25. Medical treatment included
dose of analgesics and NSAIDs per week; number of visits
to general physicians and their cost (quantiﬁed in Euros per
medical visit according to stipulated prices or established
prices per hour/professional category).
OTHER DATA
Sociodemographic and clinical data collected included
gender, age, type of cohabitation, occupational situation,
disease duration, time on waiting list for TKR, comorbidity
and previous prostheses.
ASSESSMENTS
Sociodemographic, clinical, treatment and HRQL (out-
come measures) data were determined at baseline. Out-
come measures and treatment were evaluated at 9
months (6 months after TERF) to assess the response in
the medium term. Medical visits to general physicians and
their costs were determined for the 6 months prior to and
the 6 months after the intervention. A trained interviewer
was present to provide aid if necessary to patients answer-
ing questionnaires. All assessments were performed by an
independent, blinded investigator.
STATISTICAL ANALYSIS
In the descriptive analysis, the proportion of patients in
each category or the median values were tabulated for cate-
gorical and continuous/interval variables, respectively. Base-
line characteristics of the two groups were evaluated using
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Fig. 1. Flow-chart of the program. Four out of 104 patients were not eligible because of exclusion criteria. RA (A) death in two patients, severe
pathology in one, loss of contact in two, transfer out to other autonomous communities in two, and drop out in ﬁve patients in the control group;
(B) death in two patients, severe pathology in two, loss of contact in one, and drop out in three patients in the intervention group; m¼months.the chi-square test for categorical variables and theStudent’s
t test for continuous/interval variables. It was assumed that
missing data (patients lost to the study) were missing com-
pletely at random26. To test this hypothesis, a crude logistic
regression model was constructed using ‘‘present at the
end of the study/missing at the end of study’’ as the depen-
dent variable and gender, age, occupational situation, medi-
cal treatment, WOMAC e pain, stiffness and function e and
group (TEFR or control) as independent variables.
Given the asymmetric distribution of the WOMAC func-
tion dimension variable evaluated at the end of the follow-
up, the differences were evaluated using non-parametric
tests. The Wilcoxon rank-sum test or ManneWhitney two-
sample statistic for independent groups was used to
compare each variable between the two groups and the
Wilcoxon matched-pairs signed-ranks test to compare each
variable at inclusion and at 9 months (6 months after
TERF). The differences between the two groups at 9
months (6 months after TERF), after adjustment for treat-
ment, were evaluated by linear regression for the WOMAC
function dimension, with the TERF program and treatment
as independent variables.
The conﬁdence interval was established at 95%. A value
of P 0.05 was considered statistically signiﬁcant. Thestatistical analysis was performed using the STATA (Stata
Corp. 1999. Stata Statistical Software: Release 7.0. College
Station, TX, Stata Corporation) statistical package.
Results
Of the 104 patients referred, four were excluded as they
had RA. The remaining 100 patients all agreed to partici-
pate in the study. The 100 patients were recruited between
February and October 2001. The study lasted 9 months
from October 2001 to July 2002. Patients were randomized
to the intervention group of 51 patients who received phar-
macological treatment and TEFR and the control group of
49 patients who received pharmacological treatment only.
Table I summarizes baseline sociodemographic and clin-
ical characteristics, pharmacological treatment and number
of visits to general physicians and their cost in the 6 months
prior to the study, for the two groups.
Table II shows baseline scores for the three dimensions
of the WOMAC (primary outcome) and the eight dimensions
of the SF-36. The groups were well matched in terms of
both demographic and clinical baseline details. The ﬁnal
evaluation was performed in 80 patients (n¼ 43 interven-
tion group and n¼ 37 control group). Twenty patients
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Baseline characteristics of the patients
Intervention group, n¼ 51 Control group, n¼ 49 Between group
P value
Gender: n (%)
Female 39 (76) 32 (65) 0.219*
Age
Mean (SD) 72.59 (6.20) 69.45 (6.79) 0.087y
Type of cohabitation: n (%)
Family 32 (63) 35 (72)
Alone/with carer 18 (35)/1 (2) 12 (24)/2 (4) 0.230*
Occupational situation: n (%)
Retired or housewives 45 (88) 39 (80)
Permanently disabled 5 (10) 8 (16) 0.466*
Active (sick leave) 1 (2) 2 (4)
Disease duration (m)
Mean (SD); minemax 12.06 (9.65); 1e45 11.61 (11.45); 0e53 0.834y
Time on waiting list for TKR (m)
Mean (SD); minemax 3.78 (1.75); 1e6 3.71 (1.70); 0e6 0.840y
Comorbidity: n (%) 44 (86) 43 (82) 0.826*
Prior prostheses: n (%) 19 (37) 14 (29) 0.356*
Treatment [mean (SD); minemax]
Analgesics/week 5.12 (9.35); 0e42 5.43 (10.21); 0e56 0.874y
NSAIDs/week 8.14 (7.81); 0e28 6.94 (6.86); 0e21 0.418y
Number visits to general physician (6 m prior to baseline)
Mean (SD); minemax 2.33 (2.16); 0e12 2.49 (3.11); 0e12 0.767y
Cost of visits to general physicianz (6 m prior to baseline)
Mean (SD); minemax 77.12 (71.40); 0e396.66 V 81.07 (102.18); 0e396.66 V 0.767y
Baseline variables for the two groups including sociodemographic and clinical characteristics and number of visits to general physicians and
the costs derived. None of the comparisons were statistically signiﬁcant. n: number; m: month; SD: standard deviation.
*Chi square test.
yStudent’s t test.
zCost in Euros (V).were lost to the study, eight in the intervention group (death
in two patients, severe pathology in two, loss of contact in
one, and drop out in three patients) and 12 in the control
group (death in two patients, severe pathology in one,
loss of contact in two, transfer out to other autonomous
communities in two, and drop out in ﬁve patients). Thecrude logistic regression analysis showed that there was
no evidence that the loss of patients was related to any of
the baseline characteristics or to either of the groups
(TERF or control), since the odds ratio of these variables
in the estimated models did not differ signiﬁcantly from
one with a 95% conﬁdence level.Table II
WOMAC and SF-36 scores at baseline
Intervention group n¼ 51 Control group n¼ 49 Between
group
P value*Mean Median SD Min Max Mean Median SD Min Max
WOMAC
Pain 12.29 11 7.94 4 61 10.02 10 3.91 3 20 0.077
Stiffness 4.37 4 3.16 0 20 3.81 3.5 2.06 0 8 0.302
Function 40.14 40 13.01 8 66 38.02 37 12.70 13 67 0.415
SF-36
Physical function 20.69 15 12.92 0 50 24.37 20 19.39 0 70 0.266
Physical role 25.49 0 37.58 0 100 38.02 25 42.83 0 100 0.125
Bodily pain 31.24 31 21.80 0 100 36.66 36 27.02 0 100 0.272
General health 45.39 45 19.33 10 92 49.47 49 20.97 0 97 0.313
Vitality 44.22 40 23.99 0 95 46.66 45 26.52 0 95 0.630
Social function 59.47 62 28.08 0 100 61.15 62 32.95 0 100 0.786
Emotional role 60.78 100 46.54 0 100 69.44 100 41.18 0 100 0.331
Mental health 53.16 52 24.86 0 100 58 54 23.91 8 100 0.324
WOMAC and SF-36 dimension scores at baseline. None of the comparisons were statistically signiﬁcant.
*Student’s t test.
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Outcome measures at 9 months
Intervention group (n¼ 43) Control group (n¼ 37) Between
groups*
P valuey0 months 9 months P valuez 0 months 9 months P valuez
WOMAC
Pain 12.51 8.55 10.07 3.33 0.027** 9.92 3.69 10.89 3.73 0.132 0.384
Stiffness 4.40 3.30 3.30 2.00 0.088 3.62 2.05 3.05 2.31 0.130 0.714
Function 39.81 13.75 35.26 10.48 0.032** 36.89 11.49 40.89 12.64 0.057 0.035**
SF-36
Physical function 21.34 13.51 27.20 15.49 0.031** 27.50 19.07 23.47 18.97 0.188 0.210
Physical role 26.83 38.07 34.76 44.68 0.335 40.97 42.74 49.31 42.04 0.314 0.078
Bodily pain 32.20 22.62 38.61 21.93 0.043** 37.97 25.76 30.33 24.62 0.158 0.072
General health 44.56 20.23 50.12 22.52 0.170 55.75 22.35 56.42 20.88 0.841 0.242
Vitality 43.29 24.15 51.34 23.80 0.061 49.44 25.54 54.58 25.11 0.204 0.602
Social function 58.12 27.84 61.24 30.81 0.492 62.08 35.94 62.53 32.15 0.940 0.772
Emotional role 56.10 47.99 57.71 47.16 0.847 67.58 42.56 62.03 47.26 0.535 0.618
Mental health 51.68 25.19 57.27 23.82 0.105 65.78 22.62 63.81 25.94 0.564 0.235
Treatment
Analgesics/week 4.39 7.95 8.73 8.36 0.002** 5.49 10.55 4.78 7.90 0.562 0.036**
NSAIDs/week 8.24 7.61 6.68 6.15 0.141 7.43 6.80 5.95 6.84 0.253 0.618
Number visits to
general physicianx
2.06 1.76 1.27 1.10 0.020** 2.23 2.90 1.50 1.01 0.070 0.494
Cost of visits to
general physiciank
68.05 58.08 41.87 36.35 0.020** 73.82 95.76 49.58 33.68 0.070 0.494
Results in mean SD.
*Nine months (6 months following intervention).
yManneWhitney test. **P< 0.05.
zWilcoxon matched-pairs signed rank-test.
xDifference between number of visits in the 6 months (m) prior to and the 6 months following the intervention.
kCost in Euros of the visits in the 6 months prior to and the 6 months following the study.Table III shows the changes at 6 months after the TEFR
program in the WOMAC and SF-36 questionnaires, phar-
macological treatment, visits to the general physician and
the costs derived. At 9 months (6 months after the interven-
tion), signiﬁcant differences between the two groups were
found with respect to the WOMAC function score
(P¼ 0.035) and the consumption of analgesics
(P¼ 0.036). After adjustment for treatment, the signiﬁcant
difference found in the WOMAC function score remained
(P¼ 0.018).
With respect to within-group differences, the WOMAC
score showed improvements in the intervention group in
the dimensions of pain and function (P¼ 0.027 and
P¼ 0.032, respectively) with respect to baseline. Patients
in the intervention group also showed better scores (better
quality of life) in all SF-36 dimensions with respect to base-
line, although the improvement was only statistically signif-
icant in the dimensions of physical function and bodily pain
(P¼ 0.031 and P¼ 0.043, respectively). Consumption of
analgesics in the intervention group increased signiﬁcantly
with respect to baseline (P¼ 0.002). The amount of
NSAIDs taken diminished in both groups, although not
signiﬁcantly.
There was also a signiﬁcant reduction in the number of
visits to general physicians and their cost in the 6 months
after the study in the intervention group, compared with
the 6 months prior to the study (P¼ 0.020), but not in the
control group (Table III).
Discussion
The program of TEFR for patients with knee OA is a
pioneering program in Spain and is based on principles ofself-care and self-management similar to those of edu-
cational programs established in Europe and the USA
(Arthritis Self-Management Program) for patients with joint
diseases27. Our results show that, in patients with knee
OA on a waiting list for TKR, the TEFR program produced
at 9 months (6 months after the intervention) a signiﬁcant
reduction between groups in the function dimension of the
WOMAC disease-speciﬁc questionnaire, which was consid-
ered the outcome measures of choice for any health care
intervention for OA28. In addition, there was a statistically
signiﬁcant increase in the consumption of analgesics in
the intervention group compared with controls.
Several studies have reported a worsened quality of life
in patients on a waiting list for joint replacement29,30. Patient
education has been shown, in other pathologies, to improve
the health status of patients, especially with respect to pain,
functional capacity and other quality of life variables9,10.
The results of our program are similar to those of other
studies, mainly carried out in RA patients, who found im-
provements in pain and functional capacity and a reduction
in medical visits, and improvements in other health param-
eters after the application of patient education programs:
these results are well-illustrated by the recent revision by
Newman et al.27. However, there are few studies which
evaluate the impact of education programs in patients
with knee OA31e33, although these also show improve-
ments in pain31e33, disability33, quality of life32, reduced
medical visits32, knowledge31,32 and efﬁcacy in disease
self-management31,32.
Traditional therapies for knee OA include pharmacologi-
cal or surgical interventions and exercise. Exercise has
demonstrated signiﬁcant improvements in function and
pain in older adults with knee OA11,22,34e36. Recent guide-
lines for the management of knee OA emphasize the
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ability and pain in knee OA11. Adherence is a major predic-
tor of response to exercise. Our program may have helped
to increase adherence to exercise programs and may have
favored a smaller number of patients being lost in the TEFR
group compared with the control group at the end of the fol-
low-up. Twenty patients were lost to the study but no differ-
ences were found when these were compared with patients
who completed the study. Our patients had end-stage dis-
ease and therefore it was not surprising that no signiﬁcant
improvements in pain or other disease parameters were ob-
served. We have found only one study of an exercise pro-
gram for OA patients where the disease severity is
stated35. This study of patients with Altman grade II OA
found signiﬁcant improvements in pain, disability and walk-
ing speed. This suggests that while most OA patients may
beneﬁt from comprehensive exercise programs, in patients
with end-stage disease these programs should concentrate
on maintaining or improving the function.
Pharmacologic therapy includes the use of anti-inﬂamma-
tory medications that have potentially serious long-term
side effects37. At study entry, it was observed that patients
were taking practically no analgesics and there was a pre-
dominant use of low doses of NSAIDs. The results at 9
months (6 months after the intervention) showed that, in
the intervention group, the consumption of analgesics in-
creased signiﬁcantly with respect to the control group,
whereas the number of NSAIDs diminished in both groups.
This relative increase in the consumption of analgesics
could be due to better compliance as an effect of the edu-
cational intervention. Other authors have reported that edu-
cational programs favor patient adhesion to therapeutic
guidelines that include the use of paracetamol (acetamino-
phen) as a ﬁrst step in the treatment of pain due to OA38.
The increased consumption of analgesics may also have
inﬂuenced the improvement in pain observed in the TERF
group 6 months after the intervention. No increase in ad-
verse events connected with the use of analgesics was de-
tected in routine clinical check-ups. This coincides with the
results obtained by Miceli-Richard et al.39 in a multicenter
study of 779 patients which found no secondary effects re-
lated to the use of the maximum recommended dose of par-
acetamol of 4 g/day.
Analysis of the effect of the increased consumption of
analgesics on the WOMAC scores showed no modiﬁca-
tion, and did not inﬂuence the improvement found in the
WOMAC function dimension in the intervention group. Given
that pain and stiffness are inherent physical character-
istics of the OA process, the improvement in function
may be suggested as an indicator of the success of the
TEFR program, as this type of intervention is directed at
improving physical function rather than alleviating pain
and stiffness.
Unlike the consumption of analgesics, there were no sig-
niﬁcant differences in the consumption of NSAIDs in the two
groups, although other factors, such as the risk of the indi-
rect effects of these drugs and the high comorbidity of these
patients who, frequently, are obliged to take a combination
of drugs continuously, could also have inﬂuenced this re-
duction in both groups37,40,41.
It has been suggested that individualized education pro-
grams may be better in controlling the symptoms of patients
with rheumatic diseases42. However, most programs are
carried out in groups27. Our TEFR program included individ-
ual and group visits. This allowed visits to be spaced out
over time and facilitated attendance and greater control of
the patients’ evolution. The methods used in the programachieved the speciﬁc objectives formulated; the combina-
tion of individual and group visits acted as a reinforcement
of the educational contents, while encouraging patient ad-
herence31,35. This combination of individual and group visits
could have improved adherence, as patients may have re-
ceived reinforcement from both the therapist and from fellow
patients.
The possible limitations of the present study include the
short period of follow-up and the fact that the contents of
the educational program were centered on the self-man-
agement of pain and disability in the context of the patients’
daily activities and the expectation of a TKR. This meant
that the study could not measure long-term disease self-
management, which should be one of the main objectives
of educational programs. In addition, no assessment was
performed immediately after the intervention, as our main
interest was to determine whether these patients retained
the information they had learned during their time on the
waiting list.
In conclusion, the TERF program improved physical func-
tion and increased the consumption of analgesics. To our
knowledge, this is the ﬁrst study of patients with knee OA
on a waiting list for TKR. The application of an educational
program in patients whose status can lead to further deteri-
oration of an already compromised situation deserves fur-
ther study30. Educational interventions may help to
minimize the negative impact of the period spent on
a waiting list for TKR and possibly other types of
prostheses.
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